{"entity":{"id":"da-semaglutide-evoke","kind":"drug","name":"Semaglutide (EVOKE programme)","aka":[],"tldr":"Semaglutide is FDA-approved for other indications. Alzheimer’s disease use remains investigational in Phase 3 EVOKE studies, not a dementia label.","summary":"Existing diabetes or obesity approvals do not equal a dementia indication. Alzheimer’s dosing and benefit are unproven outside trials. Not for self-directed dementia treatment.","status":"phase-3","asOf":"2026-09-21","links":[{"label":"ClinicalTrials.gov NCT04777396 (EVOKE)","url":"https://clinicaltrials.gov/study/NCT04777396"}],"tags":["dementia-atlas"],"related":[],"cancers":["alzheimers-disease","mild-cognitive-impairment"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["da-novo"],"institutions":[],"pathways":[],"terms":[],"trials":["da-trial-evoke"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Ozempic / Rybelsus / Wegovy (other indications)","modality":"small molecule","mechanism":"GLP-1 receptor agonist; Alzheimer’s cognition outcomes under study in EVOKE trials. Already labelled for diabetes/weight — not for dementia.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/da-semaglutide-evoke/","neighbours":{"cancer":[{"id":"alzheimers-disease","kind":"cancer","name":"Alzheimer’s disease","route":"/diagnoses/alzheimers-disease/"},{"id":"mild-cognitive-impairment","kind":"cancer","name":"Mild cognitive impairment","route":"/diagnoses/mild-cognitive-impairment/"}],"company":[{"id":"da-novo","kind":"company","name":"Novo Nordisk","route":"/companies/da-novo/"}],"trial":[{"id":"da-trial-evoke","kind":"trial","name":"EVOKE (semaglutide in early Alzheimer’s)","route":"/trials/da-trial-evoke/"}]}}